Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

663
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
663
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

266
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
266
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

208
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
208
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

53
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
53
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

92
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
92
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

613
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
613

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Formulation of amorphous solid dispersion of clofazimine, an extremely water-insoluble basic drug, via hot-melt extrusion by applying acid-base supersolubilization principle.

International journal of pharmaceutics·2026
Same author

Establishing experimental parameters for biphasic transfer in vitro lipolysis model.

International journal of pharmaceutics·2026
Same author

Design and application of a dissolution-permeation apparatus with scalable surface area and controllable hydrodynamic conditions at the membrane interface.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Optimizing ibuprofen dosing: insights from in vivo and virtual pharmacokinetic trials.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same author

Polymorphism in Cannabinol Piperazine Cocrystals: Structural, Morphological, and Energetic Perspectives.

Crystal growth & design·2025
Same author

High-throughput screening of amorphous solid dispersions: a systematic approach to enhance bioaccessibility of a poorly soluble drug.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025

関連する実験動画

Updated: Feb 26, 2026

Preparation of Binary and Ternary Deep Eutectic Systems
06:15

Preparation of Binary and Ternary Deep Eutectic Systems

Published on: October 31, 2019

12.8K

深共晶体系を可能にする医薬品製剤:メカニズムと応用

Shaida Panbachi1, Josef Beránek2, Martin Kuentz3

  • 1University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
|February 24, 2026
PubMed
まとめ

深共晶系(DES)は薬物の溶解度を高め、経口バイオアベイラビリティを改善し、環境への影響を低減する。これらの新しい製剤は、溶解度の低い医薬品化合物を開発するための持続可能なソリューションを提供する。

キーワード:
可能にする製剤、溶解度増強、深共晶溶媒、多成分系、過飽和、治療用深共晶溶媒

さらに関連する動画

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.6K
Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

10.2K

関連する実験動画

Last Updated: Feb 26, 2026

Preparation of Binary and Ternary Deep Eutectic Systems
06:15

Preparation of Binary and Ternary Deep Eutectic Systems

Published on: October 31, 2019

12.8K
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.6K
Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

10.2K

科学分野:

  • 製薬科学;グリーンケミストリー;化学工学

背景:

  • 多くの新しい医薬品化合物は、水溶性が低いために開発に失敗している。
  • 深共晶系(DES)は、製剤における溶解度増強のための有望なソリューションとして登場している。

研究 の 目的:

  • DESとその特性を類似システムと比較して紹介する。
  • 製剤応用のための共晶、DES、および治療用DES(THEDES)をレビューする。
  • 溶解度と毒性などのDES特性に関する計算研究の概要を説明する。

主な方法:

  • 医薬品におけるDES応用の文献レビュー。
  • DESと他の多成分系の比較分析。
  • DES特性の研究のための計算技術の概要。

主要な成果:

  • DESは溶解度の低い化合物に有効な可溶化剤である。
  • DESは医薬品を可能にする製剤として利用できる。
  • 計算研究はDESの溶解度と毒性に関する洞察を提供する。

結論:

  • DES液体は、溶解度を可能にする製剤のための実行可能な戦略を提供する。
  • DESからの経口バイオアベイラビリティの増加は、生体医薬品の性能を向上させ、APIの廃棄物を削減する。
  • DESの応用は、医薬品開発における持続可能なアプローチを表す。